Dose-Modified Lenalidomide Induces Sustained Hematological Response in Patients With Intermediate to High Risk Myelodysplasia. Mediterr J Hematol Infect Dis 2010, 2 (2), e2010012. https://doi.org/10.4084/mjhid.2010.012.